Ireland-headquartered drugmaker Shire (LSE: SHP) revealed on Friday that the US Food and Drug Administration has requested an additional clinical study as part of a complete response letter (CRL) to the company’s new drug application for Lifitegrast for the signs and symptoms of dry eye disease in adults.
The news comes just over a week before the FDA Prescription Drug User Fee Act V action date of October 25 for this dry eye disease, which analysts have forecast has a $1 billion-a-year-plus sales potential.
New data submission to FDA expected in 1st-qtr 2016
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze